GCM
OTLK icon

Gables Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Gables Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,975
Closed -$58.6K – 448
2024
Q3 		$58.6K Sell
10,975
-350
-3% -$2.56K 0.03% 201
2024
Q2 		$83.6K Buy
11,325
+1,600
+16% +$12.8K 0.04% 170
2024
Q1 		$116K Buy
9,725
+2,400
+33% +$19.4K 0.06% 143
2023
Q4 		$57.7K Sell
7,325
-400
-5% -$3.38K 0.04% 181
2023
Q3 		$34.1K Buy
7,725
+4,400
+132% +$97.3K 0.02% 214
2023
Q2 		$116K Hold
3,325
– – 0.08% 142
2023
Q1 		$72.5K Hold
3,325
– – 0.05% 163
2022
Q4 		$71.8K Buy
3,325
+250
+8% +$5.44K 0.05% 171
2022
Q3 		$75K Hold
3,075
– – 0.06% 161
2022
Q2 		$63K Buy
3,075
+750
+32% +$21.6K 0.05% 182
2022
Q1 		$83K Buy
2,325
+2,150
+1,229% +$67.1K 0.05% 176
2021
Q4 		$5K Buy
+175
New +$6.24K ﹤0.01% 325

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Gables Capital Management's OTLK Position: Q4 2024 in Review

Gables Capital Management sold out of Outlook Therapeutics (OTLK) in Q4 2024, closing a stake of 10,975 shares — an estimated $58.6K sold.

Gables Capital Management first reported a position in OTLK in Q4 2021 and held it in 12 quarters. The position peaked at $116K in Q1 2024. 61 funds tracked by Wall St. Rank hold OTLK as of Q4 2024.

  • Gables Capital Management reported no remaining Outlook Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Gables Capital Management sold 10,975 Outlook Therapeutics shares in Q4 2024, an estimated $58.6K.
  • Gables Capital Management first reported a position in Outlook Therapeutics in Q4 2021 and held it in 12 quarters.
  • Gables Capital Management's Outlook Therapeutics position peaked at $116K in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2024.

Based on Gables Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.